Discover why early detection for Alzheimer’s & Parkinson’s has been so challenging until now, and why fighting Alzheimer’s disease is critically important on a global scale.
Meet Amprion, a biotech company with groundbreaking Early Prion Detection Science to track the biomarkers (aka prion-particles or misfolded proteins) that cause these neurodegenerative diseases. Amprion’s revolutionary early detection technology tracks all three misfolded proteins: Abeta amyloid, Tau and Synuclein prior to any clinical symptoms. Our mission is to empower people to navigate their brain health.
We’re fighting against Alzheimer’s and Parkinson’s. Join the Fight! #JTFBrainHealth
Amprion Breakthrough Early Detection for Alzheimer’s & Parkinson’s
The brain is a mysterious organ. Scientists are working to better understand the effects of brain aging. At Amprion, we’re working hard to perform early detection for Alzheimer’s & Parkinson’s before they destroy our brains.
Every 33 seconds, one American will be diagnosed with Alzheimer’s by 2050, adding to the millions of existing patients that as of yet have no cure. Today five million people in the U.S. are diagnosed with Alzheimer’s and one million with Parkinson’s. These numbers are expected to triple by 2050. In the past three decades, it is estimated over a $100 billion dollars were spent in drug development and clinical trials for Alzheimer’s and Parkinson’s and yet none of these efforts have yielded effective treatments.
Population aging is a global phenomenon. In China alone, nearly 30 million people will be diagnosed with Alzheimer’s by 2050. Global cost for these patients is estimated at $10 trillion dollars a year and this problem is growing. So finding a cure for Alzheimer’s and Parkinson’s is priority number one. The key to success in finding a cure is early detection. However, this has not been possible… until Amprion.
So Why has Early Detection for Alzheimer’s & Parkinson’s been so Challenging?
Today the main problem for clinical diagnosis is that the Parkinson’s and Alzheimer’s diagnosis is based on symptoms, and symptoms come after a large part of the brain is destroyed. Alzheimer’s and Parkinson’s are caused by misfolded proteins in the brain that produce toxicity, kill neurons and destroy the brain. So the misfolded proteins although accumulate in the brain, it’s known that they travel everywhere in the body, through the blood, present in many different tissues, and even secrete in urine, but the amount is so small that it’s really impossible to detect by any standard techniques.
The main challenge to track this process is that these misfolded proteins accumulate in large amount only in the brain. The brain is a difficult tissue to access. You cannot do a brain biopsy for diagnosis. So the amount of material circulating in biological fluids is very small, especially in the beginning of the process.
It turns out that Alzheimer’s and Parkinson’s and other neurodegenerative diseases function differently from cancer in the sense that it’s probably not caused by specific mutations, it’s caused by normal proteins misfolding as we age into shapes that are not normal but that are toxic. We extend what anyone can do with genetics and we believe that looking at misfolded proteins is the future for classes of diseases where we have not been particularly successful in developing drugs previously.
At Amprion, we amplify prions, so if there’s a very small amount normally in the brain we allow one to see this much earlier and therefore, we allow early diagnosis because we detect biomarkers at very, very low concentrations prior to there being any disease. We believe that we might be able to extend early detection to decades or more. At Amprion, we have found a way to give people a reliable, accurate and early detection for Alzheimer’s and Parkinson’s. We empower people, by giving them control over their brain health.
Related Articles on Early Detection of Alzheimer’s & Parkinson’s:
- The Origin Story | Early Detection for Alzheimer’s and Parkinson’s
- Prion Early Detection Science℠
- Sensitive & Early Diagnosis of Alzheimer’s Disease
- Protein Misfolding in Neurodegenerative Brain Diseases: The Key Questions